Your browser is no longer supported. Please, upgrade your browser.
Settings
ABBV AbbVie Inc. daily Stock Chart
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E17.08 EPS (ttm)6.22 Insider Own0.10% Shs Outstand1.59B Perf Week0.32%
Market Cap169.01B Forward P/E11.91 EPS next Y8.92 Insider Trans-24.65% Shs Float1.59B Perf Month14.72%
Income9.96B PEG0.99 EPS next Q1.97 Inst Own71.70% Short Float1.18% Perf Quarter-9.96%
Sales29.61B P/S5.71 EPS this Y52.60% Inst Trans-0.52% Short Ratio2.63 Perf Half Y12.45%
Book/sh2.23 P/B47.64 EPS next Y14.71% ROA9.20% Target Price115.90 Perf Year61.99%
Cash/sh5.95 P/C17.84 EPS next 5Y17.27% ROE119.30% 52W Range64.80 - 125.86 Perf YTD9.84%
Dividend3.84 P/FCF29.48 EPS past 5Y10.60% ROI25.40% 52W High-15.60% Beta1.63
Dividend %3.61% Quick Ratio1.10 Sales past 5Y9.00% Gross Margin75.80% 52W Low63.94% ATR2.19
Employees29000 Current Ratio1.20 Sales Q/Q21.40% Oper. Margin34.00% RSI (14)66.20 Volatility1.45% 2.17%
OptionableYes Debt/Eq10.49 EPS Q/Q64.20% Profit Margin21.50% Rel Volume0.81 Prev Close105.98
ShortableYes LT Debt/Eq8.70 EarningsApr 26 BMO Payout65.90% Avg Volume7.12M Price106.23
Recom2.30 SMA205.93% SMA506.14% SMA20010.45% Volume5,797,277 Change0.24%
Jan-30-18Reiterated Morgan Stanley Equal-Weight $99 → $131
Jan-29-18Downgrade Leerink Partners Outperform → Mkt Perform
Oct-30-17Reiterated Leerink Partners Outperform $108 → $107
Oct-02-17Upgrade Leerink Partners Mkt Perform → Outperform
Sep-25-17Downgrade UBS Buy → Neutral $79 → $92
Aug-17-17Initiated Evercore ISI Outperform $95
Jun-22-17Upgrade Societe Generale Hold → Buy
Mar-22-17Upgrade Societe Generale Sell → Hold
Oct-31-16Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Mkt Perform $70
Sep-08-16Downgrade JP Morgan Overweight → Neutral
Sep-02-16Initiated Raymond James Outperform $82
Jun-08-16Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-06-16Initiated Societe Generale Sell $47
Mar-15-16Initiated Deutsche Bank Hold $63
Feb-23-16Upgrade Citigroup Neutral → Buy
Dec-01-15Downgrade Barclays Overweight → Equal Weight $73 → $72
Nov-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-23-15Reiterated UBS Buy $81 → $78
Sep-28-15Upgrade Citigroup Sell → Neutral
May-21-18 02:25PM  Roche (RHHBY) Announces Positive Data on Hemophilia Drug Zacks
10:53AM  Top Analyst Reports for Procter & Gamble, AbbVie, McDonald's & PepsiCo Zacks
07:15AM  Bristol-Myers Squibb and Three Additional Stocks Under Scanner in the Drug Makers Space ACCESSWIRE
May-18-18 08:15AM  5 Things AbbVie Investors Need to Know Motley Fool
May-16-18 04:59PM  AbbVie to Show Progress and Growth in Oncology Research at the American Society of Clinical Oncology 2018 Annual Meeting PR Newswire
May-15-18 05:09PM  Trumps Attempt to Shame Drugmakers Shows Medicare Costs Soaring Bloomberg
06:00AM  3 Top Healthcare Stocks to Buy in May Motley Fool
May-14-18 01:25PM  The Trump Plan To Reduce Prescription Drug Prices Will Have A Major Impact Forbes
May-11-18 04:02PM  Why Do 113 Top-Rated Funds Own Shares In This Breakout Cloud Stock? Investor's Business Daily
May-10-18 06:49PM  3 Dividend Stocks for In-the-Know Investors Motley Fool
May-09-18 06:00AM  3 Top Biotech Stocks to Buy in May Motley Fool
May-08-18 08:00AM  AbbVie to Present at the UBS Global Healthcare Conference PR Newswire
May-04-18 04:06PM  Pharma Stock Roundup: Mixed Q1 for MRK, PFE, FDA Nod for Kymriah's 2nd Indication Zacks
07:00AM  Is Gilead Sciences Stock Finally a Bargain? Motley Fool
May-03-18 01:58PM  Top 5 Biotech Stocks for 2018 Investopedia
10:23AM  Did Gilead Sciences Make a Big Mistake? Motley Fool
10:15AM  NBIX: Strong INGREZZA® Sales Continue in 1Q18; Expanding Sales Team for Future Growth Zacks Small Cap Research
09:11AM  Drugmakers eye a new threat to sales but say it hasnt affected them yet MarketWatch
08:45AM  Your first trade for Thursday, May 3 CNBC
May-02-18 05:59PM  "Fast Money" final trades: SNAP, SPOT and more CNBC Videos
05:15PM  Top 4 Marijuana Stocks to Watch Investopedia
01:39PM  9 Winning Stocks as the Bull Loses Steam Investopedia
08:00AM  AbbVie to Present at the 2018 Bank of America Merrill Lynch Health Care Conference PR Newswire
06:03AM  Better Buy: Johnson & Johnson (JNJ) vs. AbbVie (ABBV) Motley Fool
06:01AM  Gilead Sciences' First-Quarter Twist: Weak HIV Sales Motley Fool
May-01-18 04:33PM  Seagate, Pfizer and Cummins skid while AbbVie jumps Associated Press +5.72%
04:31PM  Why Nutrisystem, Tenet Healthcare, and AbbVie Jumped Today Motley Fool
09:32AM  How AbbVie Makes its Money Investopedia
08:45AM  AbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis PR Newswire
07:47AM  AbbVie Commences Self-Tender Offer for Up to $7.5 Billion of its Common Stock PR Newswire
04:31AM  [$$] Gilead shares rattled by sharp slide in hepatitis C drug sales Financial Times
Apr-30-18 11:35AM  AbbVie and Rice University establish K.C. Nicolaou Research Accelerator to advance therapies in oncology PR Newswire
10:11AM  Drug Stocks Q1 Earnings to Watch on May 1: PFE, MRK & More Zacks
Apr-28-18 02:03PM  AbbVie's First Quarter: Can We Quit Worrying About Humira Now? Motley Fool
Apr-27-18 08:18AM  3 Things You Need to Know About AbbVie's Monster Q1 Earnings Motley Fool
08:00AM  AbbVie Presents New Investigational Data for Elagolix at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting PR Newswire
Apr-26-18 11:59PM  Edited Transcript of ABBV earnings conference call or presentation 26-Apr-18 1:00pm GMT Thomson Reuters StreetEvents +6.06%
04:29PM  How AbbVie 'Crushed It' On Hepatitis C As Fellow Drugmaker Bristol Dips Investor's Business Daily
02:23PM  AbbVie Inc. -- Moody's: AbbVie's share repurchase acceleration credit negative Moody's
02:05PM  There are a lot of 'table-pounding buys' in the market now: Value investor David Katz CNBC
01:18PM  DaVIta (DVA) to Report Q1 Earnings: Is a Beat in Store? Zacks
01:06PM  A Look At The Intrinsic Value Of AbbVie Inc (NYSE:ABBV) Simply Wall St.
12:26PM  AbbVie (ABBV) Q1 Earnings Beat, 2018 View Up, Stock Gains Zacks
11:24AM  AbbVie Inc Stock Up on Strong Earnings, Guidance Update InvestorPlace
11:00AM  Is a Beat in the Cards for Gilead (GILD) in Q1 Earnings? Zacks
10:52AM  Sales Of AbbVie's Hepatitis C Drugs Soar Forbes
10:05AM  Drug Makers: A Dose of Robust Earnings Barrons.com
08:36AM  AbbVie (ABBV) Tops Q1 Earnings and Revenues, View Up Zacks
08:29AM  [$$] AbbVie unveils $7.5bn share buyback Financial Times
08:28AM  How AbbVie 'Crushed It' On Hepatitis C As Fellow Drugmaker Bristol Dips Investor's Business Daily
08:08AM  AbbVie: 1Q Earnings Snapshot Associated Press
08:00AM  AbbVie shares rise 3% on Q1 profit, revenue beats and $7.5 billion share buyback MarketWatch
07:48AM  AbbVie beats quarterly revenue estimates, raises earnings forecast Reuters
07:47AM  AbbVie Reports First-Quarter 2018 Financial Results PR Newswire
Apr-25-18 12:25PM  Shire willing to back $64 billion Takeda bid, market signals doubts Reuters
10:56AM  Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX Zacks
08:45AM  AbbVie Submits Biologics License Application to U.S. FDA for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis PR Newswire
08:30AM  AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients PR Newswire
Apr-24-18 09:55PM  Supreme Court upholds legality of patent review process Reuters
04:56PM  U.S. Supreme Court upholds legality of patent review process Reuters
11:53AM  Is a Beat in the Cards for AbbVie (ABBV) in Q1 Earnings? Zacks
11:46AM  Biogen (BIIB) Q1 Earnings Beat, Sales Miss, Shares Down Zacks
11:42AM  How Does Biogen Make its Money? Investopedia
11:29AM  U.S. Supreme Court upholds legality of patent review process Reuters
10:10AM  U.S. Supreme Court upholds legality of patent review process Reuters
09:31AM  This Small Biotech Is Building on a Surprising Success Motley Fool
08:32AM  Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma Motley Fool
06:00AM  Amid drug price worries, earnings to test U.S. pharma, biotech shares Reuters
Apr-23-18 04:36PM  Amid drug price worries, earnings to test U.S. pharma, biotech shares Reuters
11:33AM  Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy Zacks
Apr-20-18 09:02AM  AbbVie And Other Great Pharma And Biotech Income Stocks Simply Wall St.
Apr-19-18 02:30PM  Mylan NV Could Be Closer to a Breakout Than Most Traders Realize InvestorPlace
04:27AM  Moody's: Stable outlook for global pharmaceuticals, M&A event risk is rising Moody's
Apr-18-18 06:54PM  Roche Hemophilia Drug Gets Breakthrough Therapy Designation Zacks
08:00AM  AbbVie to Present at the Deutsche Bank's 43rd Annual Health Care Conference PR Newswire
06:47AM  The Zacks Analyst Blog Highlights: AbbVie, Berkshire Hathaway, PepsiCo, BP and Twenty-First Century Fox Zacks
Apr-17-18 03:42PM  Top Analyst Reports for AbbVie, Berkshire & PepsiCo Zacks
02:00PM  7 Stock Picks With Giant Upside: Goldman Investopedia
11:48AM  5 Drug Stocks Poised to Surpass on Earnings This Quarter Zacks
Apr-16-18 08:15AM  Consolidated Research: 2018 Summary Expectations for Amazon, Rayonier, The Boeing, Sanchez Energy, AbbVie, and American Airlines Group Fundamental Analysis, Key Performance Indications GlobeNewswire
Apr-13-18 03:20PM  Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III Zacks
08:18AM  Better Buy: AbbVie Inc. vs. Eli Lilly Motley Fool
Apr-12-18 05:53PM  Mylan Fujifilm Kyowa Team Up to Market Humira Biosimilar Zacks
09:39AM  AbbVie Stock Is Signaling That a Move to the Upside Could Be Near Investopedia
Apr-11-18 11:36AM  FDA Prolongs Review Date for AbbVie Endometriosis Candidate Zacks
10:20AM  Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis Zacks
07:50AM  Ex-Dividend Alert: Boosted its Dividend by Whopping 35%; Will Trade Ex-Dividend on April 12, 2018 ACCESSWIRE
06:03AM  Is Gilead Sciences, Inc. (GILD) a Buy? Motley Fool
Apr-10-18 04:40PM  AbbVie's RA Candidate Meets Primary Endpoints in Phase III Zacks
10:16AM  FDA needs more time to review AbbVie, Neurocrine's uterine pain drug Reuters
09:05AM  UPDATE 1-FDA needs more time to review AbbVie, Neurocrine's uterine pain drug Reuters
09:05AM  FDA extends review for AbbVie, Neurocrine's uterine pain drug Reuters
08:15AM  AbbVie and Neurocrine Biosciences Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain PR Newswire
Apr-09-18 08:54AM  AbbVie shares jump 2.2% on news of positive results in rheumatoid arthritis drug trial MarketWatch
08:45AM  Upadacitinib Meets All Primary and Ranked Secondary Endpoints Including Superiority Versus Adalimumab in Phase 3 Study in Rheumatoid Arthritis PR Newswire
06:00AM  3 Reasons This Clinical-Stage Biotech Is an Incredible Bargain Motley Fool
01:37AM  [$$] Merck eyes best day since 2016, gains help fuel pharma rally Financial Times
Apr-08-18 04:26PM  Here's Why AbbVie Inc. Fell 18.3% in March Motley Fool
Apr-06-18 07:45PM  3 High-Yield Stocks at Rock-Bottom Prices Motley Fool
11:06AM  Biogen Cracks the Case With AbbVie for Humira Biosimilar Zacks
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has a strategic collaboration with Alector, Inc.; C2N Diagnostics; Voyager Therapeutics, Inc.; Janssen Biotech, Inc.; and International Myeloma Foundation. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ALBAN CARLOSEVP, Commercial OperationsMar 01Option Exercise29.2348,1001,405,795178,547Mar 02 05:29 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMar 01Option Exercise25.9132,400839,339197,263Mar 02 05:28 PM
Schumacher Laura JExecutive Vice PresidentMar 01Sale117.8525,0002,946,14898,317Mar 02 05:28 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMar 01Sale114.5032,4003,709,687164,863Mar 02 05:28 PM
ALBAN CARLOSEVP, Commercial OperationsMar 01Sale114.3980,9959,264,80897,552Mar 02 05:29 PM
Michael Robert A.VP, ControllerFeb 28Sale119.434,294512,8536,876Mar 02 05:31 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 28Sale117.771,337157,45893,312Mar 02 05:31 PM
SEVERINO MICHAELEVP, R&D and CSOFeb 28Sale117.932,643311,684132,281Mar 02 05:30 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 28Sale118.6718,1292,151,45217,588Mar 02 05:30 PM
CHASE WILLIAM JEVP, Chief Financial OfficerFeb 28Sale119.4438,5284,601,954164,863Mar 02 05:28 PM
ALBAN CARLOSEVP, Commercial OperationsFeb 28Sale117.852,579303,928130,447Mar 02 05:29 PM
GONZALEZ RICHARD AChairman of the Board and CEOFeb 28Sale117.888,280976,084313,012Mar 02 05:28 PM
Michael Robert A.VP, ControllerFeb 20Sale120.31992119,35113,557Feb 20 06:08 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesDec 18Option Exercise35.8887,0403,122,995113,118Dec 19 06:09 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesDec 18Sale98.4587,0408,569,05326,078Dec 19 06:09 PM
Schumacher Laura JExecutive Vice PresidentDec 15Option Exercise35.881,14341,011106,875Dec 15 05:13 PM
Schumacher Laura JExecutive Vice PresidentDec 14Option Exercise35.88144,3675,179,888250,099Dec 15 05:13 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 21Option Exercise58.88218,19312,847,204492,030Nov 24 04:55 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 21Sale94.01218,19320,511,800273,837Nov 24 04:55 PM
SEVERINO MICHAELEVP, R&D and CSONov 10Sale94.6925,6332,427,212114,922Nov 13 05:26 PM
Gosebruch Henry OChief Strategy OfficerOct 30Sale90.5518,3001,657,03765,137Oct 31 05:04 PM
Michael Robert A.VP, ControllerSep 28Sale88.006,699589,51210,007Sep 29 05:02 PM
SALEKI-GERHARDT AZITASVP, OperationsSep 11Option Exercise24.214,800116,19993,099Sep 12 05:40 PM
SALEKI-GERHARDT AZITASVP, OperationsSep 11Sale85.028,300705,65584,799Sep 12 05:40 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 07Option Exercise51.42193,1319,930,796469,623Aug 08 07:26 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 07Sale71.00193,13113,713,186276,492Aug 08 07:26 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 04Option Exercise51.4222,0381,133,194364,391Aug 04 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 04Sale71.0722,0381,566,166276,492Aug 04 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 03Option Exercise51.4265,8613,386,573342,353Aug 04 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 03Sale71.0065,8614,676,131298,530Aug 04 05:01 PM
RAPP EDWARD JDirectorJul 31Buy70.454,000281,78215,498Aug 02 05:05 PM
Gosebruch Henry OChief Strategy OfficerJul 31Sale70.0918,0001,261,63883,737Aug 02 05:05 PM
Gosebruch Henry OChief Strategy OfficerJul 31Sale70.4230021,12783,437Aug 02 05:06 PM
ALBAN CARLOSEVP, Commercial OperationsJun 14Option Exercise24.2145,8001,108,736160,545Jun 15 05:05 PM
Schumacher Laura JExecutive Vice PresidentJun 14Option Exercise29.2379,8002,332,275187,625Jun 15 05:05 PM
ALBAN CARLOSEVP, Commercial OperationsJun 14Sale70.0045,8003,206,000114,745Jun 15 05:05 PM
Schumacher Laura JExecutive Vice PresidentJun 14Sale70.0079,8005,586,000107,825Jun 15 05:05 PM